Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072781 · ClinicalTrials.gov registry record · Phase 3
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
A Phase 3 study of Low-Grade Serous Ovarian Cancer, sponsored by Verastem.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06072781: Recruiting Phase 3 study of Low-Grade Serous Ovarian Cancer, sponsored by Verastem.
NCT06072781 is a Phase 3 study of Low-Grade Serous Ovarian Cancer that is actively recruiting participants, run by Verastem. The registered enrollment target is 270 participants. The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06072781, a Phase 3 study of Low-Grade Serous Ovarian Cancer, is actively recruiting participants, sponsored by Verastem.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Conditions Studied
Interventions
- DRUG Defactinib
- DRUG Paclitaxel
- DRUG Letrozole
- DRUG Pegylated liposomal doxorubicin
- DRUG avutometinib
Study Locations (20)
Florida
- Florida Cancer Specialists - South - Fort Myers
- Mount Sinai - Miami Beach
- AdventHealth - Orlando
- Moffitt Cancer Center - Tampa
- Florida Cancer Specialists Research East - West Palm Beach
California
- UCLA Health - Los Angeles
- UC Davis - Sacramento
- University of California, San Francisco - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
- Memorial Sloan Kettering Cancer Center - New York
Arizona
- HonorHealth - Phoenix
Arkansas
- University of Arkansas - Little Rock
Connecticut
- Yale University - New Haven
Georgia
- Winship Cancer Institute at Emory University - Atlanta
Illinois
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2024-03-18 |
| Est. Completion | 2031-02-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072781
The ClinicalTrials.gov registry entry for NCT06072781 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verastem, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Low-Grade Serous Ovarian Cancer appearing as the primary indexed condition, and to 5 interventions - of which Defactinib is the first listed.
NCT06072781 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, New York.
Frequently Asked Questions
What is clinical trial NCT06072781 about?
NCT06072781 is a clinical study titled "A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer". This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
What is the current status of trial NCT06072781?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 270 participants. The study started on 2024-03-18. Estimated completion is 2031-02-09.
What conditions does trial NCT06072781 study?
This clinical trial studies the following conditions: Low-Grade Serous Ovarian Cancer.
What interventions are being tested in trial NCT06072781?
The interventions under investigation include: Defactinib (DRUG), Paclitaxel (DRUG), Letrozole (DRUG), Pegylated liposomal doxorubicin (DRUG), avutometinib (DRUG).
Who is sponsoring clinical trial NCT06072781?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072781 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Low-Grade Serous Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
RECRUITING · Phase 2
-
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.